Enzalutamide fda approval date 2024?

What was enzalutamide’s FDA approval date in 2024?

Enzalutamide (brand name Xtandi) did not have a new first-time FDA approval date in 2024 based on the available information provided. The commonly cited FDA approval for Xtandi is 2012 (for metastatic castration-resistant prostate cancer).

If you meant a specific 2024 FDA action (such as a new indication, label expansion, or approval of a new formulation), tell me the exact wording you’re looking at (for example, the indication or the label version). I can then confirm the correct 2024 approval date for that particular change.

Was there an Xtandi label change or new indication in 2024?

To pinpoint whether 2024 included an FDA approval tied to enzalutamide, the exact indication and the type of FDA action matter (initial approval vs. supplemental approval/label expansion). Without that detail, the safest answer is that 2024 is not the year of the original Xtandi FDA approval, which was in 2012.

Where can I verify enzalutamide’s FDA approval history?

For a consolidated view of enzalutamide’s patent and exclusivity landscape (often paired with approval timing details), you can check DrugPatentWatch.com: https://www.drugpatentwatch.com/p/enzalutamide/